Navigation Links
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Date:12/6/2010

for this reason. The overall rate of discontinuation due to adverse events was 16%(1).

About LBH589Because it is an investigational compound, the safety and efficacy profile of LBH589 has not yet been established. Access to this investigational compound is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. Because of uncertainty of clinical trials, there is no guarantee that LBH589 will ever be commercially available anywhere in the world.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "planned," "investigational," "potential," "investigating," "ongoing," "encouraging," "committed," "promising," or similar expressions, or by express or implied discussions regarding potential future approvals to market LBH589, or regarding potential future revenues from LBH589. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that LBH589 will be submitted or approved for sale in any market, or that LBH589 will achieve any particular revenue levels. In particular, management's expectations could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact t
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Md. , Oct. 17, 2014 ... for Medical Technology Policy: The Green ... the FDA, public and private payers, medical device ... clinicians, and other experts January 12, 2015 at ... and value of weight loss treatments.  Participants will ...
(Date:10/17/2014)...   InnFocus, Inc ., reported on results of 59 ... for up to 3 years with the InnFocus MicroShunt® ... Chicago . The Summit ... of the American Academy of Ophthalmology . The Company ... patients in 6 countries by early 2015. Logo ...
(Date:10/17/2014)... Mass. , Oct. 17, 2014   ndd ... function testing (PFT) employing precise ultrasound technology, announced that ... Choctaw Nation Healthcare Center , a 140,000 square ... Talihina, Oklahoma hospital serves a large ... southeastern Oklahoma and beyond. A ...
Breaking Medicine Technology:Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
... N.J., Oct. 25, 2011 Omthera Pharmaceuticals, Inc., a ... J. Maines has joined the Company as Vice President ... to Chief Operating Officer, Drs. Ben Machielse, Mr. Maines ... at Omthera.   Mr. Maines brings to ...
... N.C., Oct. 25, 2011 GlaxoSmithKline, one of ... today announced the 10 winners of its GlaxoSmithKline ... Philadelphia-area healthcare nonprofit organizations will receive $400,000 in ... the underserved in their communities. Three ...
Cached Medicine Technology:Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 3
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... 20, 2014 This report provides ... Seizure, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ... special features on late-stage and discontinued projects. , ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... , SUNDAY, March 20 (HealthDay News) -- Firstborn ... of allergies, finds a new study. Japanese researchers surveyed ... and found that a child,s birth order did not seem ... firstborn children were more likely to have hay fever, pink ...
... San Diego, Calif., USA Today, during the 89th ... Dental Research, held in conjunction with the 40th Annual ... the 35th Annual Meeting of the Canadian Association for ... oral presentation on a research study titled "Biodegradable Tooth-binding ...
... Jenifer Goodwin HealthDay Reporter , FRIDAY, March ... an advisory panel to the U.S. Food and Drug ... and their removal "from the marketplace would benefit public ... Scientific Advisory Committee also said that menthols, minty flavor ...
... -- Girls in early adolescence who form friendships with boys ... a new research. The study included 400 female and ... interviewed annually over seven years about their friendship network and ... girls tend to limit their friendships to same-sex peers. But ...
... (HealthDay News) -- Orthodontic retainers, removable devices used to keep ... if they aren,t properly cleaned, finds a new study. ... of a group of study participants and found that about ... that can cause fungal infections, while 50 percent had ...
... will likely be the hardest hit as a result of ... previous catastrophic events. Approximately 23 percent of Japanese citizens currently ... the highest proportion of older people in any country ... whole is headed," said James Appleby, RPh, MPH, executive director ...
Cached Medicine News:Health News:Biodegradable tooth-binding micelles inhibit Streptococcus mutans biofilm growth 2Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 2Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 3Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 4Health News:Teen Girls Who Befriend Boys at Higher Risk for Substance Abuse 2Health News:Orthodontic Retainers Can Harbor Harmful Microbes 2Health News:Japanese tsunami underscores need for elder disaster preparedness 2
The ACP 215 is the automated closed system cell processor with integrated process control....
... throughout the world are facing difficult times ... of the blood supply in the face ... donor base. Clearly, these centers must find ... manage their existing donor pools, and to ...
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
Medicine Products: